Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Weill Medical College of Cornell University
30 participants
Jun 8, 2026
INTERVENTIONAL
Conditions
Summary
This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.
Eligibility
Inclusion Criteria12
- Biologically female
- Age ≥ 18
- Obesity as defined by current BMI ≥ 30 kg/m²
- Postmenopausal as defined by one or more of the following
- Age ≥60 years
- Age <60 years with amenorrhea for ≥ 1 year
- Documented bilateral surgical oophorectomy
- Chemical menopause with the addition of LHRH agonists at least 12 weeks prior to enrolment, and plan to remain on LHRH agonists throughout the trial
- HR+ (ER and/or PR) stage 0-III breast cancer
- Completed curative treatment (surgery, chemotherapy, radiotherapy) at least 12 weeks prior to enrolment
- Insurance approval for tirzepatide or willing to pay out of pocket
- Willing to provide informed consent and comply with study procedures
Exclusion Criteria9
- Stage IV breast cancer
- Concomitant use of CDK inhibitors
- Concomitant use of antiHER2 therapy
- The PI may be consulted regarding enrollment of females receiving other endocrine therapy medications
- Other active malignancy requiring treatment
- Enrollment in another investigational clinical trial
- Contraindication to tirzepatide
- Treatment with a GLP-1 receptor agonist within the last 3 months
- Diabetes requiring insulin
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will take tirzepatide weekly for 24 weeks. The dose will be adjusted on a monthly basis as clinically indicated.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07257484